Microbot Medical (MBOT) 10-Q 17 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 16, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-19871
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	25 Recreation Park Drive
Entity Address, Address Line Two	Unit 108
Entity Address, City or Town	Hingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02043
City Area Code	(781)
Local Phone Number	875-3605
Title of 12(b) Security	Common Stock
Trading Symbol	MBOT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,130,628

Interim Consolidated Balance Sh

Interim Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,150	$ 2,442
Marketable securities	2,907	5,760
Short-term deposit		3
Restricted cash	49	77
Prepaid expenses and other current assets	475	532
Total current assets	5,581	8,814
Property and equipment, net	196	221
Operating right-of-use assets	431	502
Total assets	6,208	9,537
Current liabilities:
Accounts payable	224	116
Lease liabilities	266	283
Accrued liabilities	743	1,670
Total current liabilities	1,233	2,069
Non-current liabilities:
Long-term lease liabilities	127	179
Total liabilities	1,360	2,248
Stockholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 8,130,628 and 7,890,628 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively.	83	80
Additional paid-in capital	76,379	75,970
Accumulated deficit	(71,614)	(68,761)
Total stockholders’ equity	4,848	7,289
Total liabilities and stockholders’ equity	$ 6,208	$ 9,537

Interim Consolidated Balance _2

Interim Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	8,130,628	7,890,628
Common stock, shares outstanding	8,130,628	7,890,628

Interim Consolidated Statements

Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Research and development	$ (1,617)	$ (1,706)
General and administrative	(1,302)	(1,470)
Operating loss	(2,919)	(3,176)
Financing income (expenses), net	66	(13)
Net loss	$ (2,853)	$ (3,189)
Basic and diluted net loss per share	$ (0.36)	$ (0.45)
Basic and diluted weighted average common shares outstanding	8,013,295	7,108,133

Interim Consolidated Statemen_2

Interim Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 72	$ 69,902	$ (55,593)	$ 14,381
Balance, shares at Dec. 31, 2021	7,108,133
Share-based compensation		429		429
Net loss			(3,189)	(3,189)
Balance at Mar. 31, 2022	$ 72	70,331	(58,782)	11,621
Balance, shares at Mar. 31, 2022	7,108,133
Balance at Dec. 31, 2022	$ 80	75,970	(68,761)	7,289
Balance, shares at Dec. 31, 2022	7,890,628
Share-based compensation		412		412
Net loss			(2,853)	(2,853)
Issuance of common stock upon exercise of warrants	$ 3	(3)
Issuance of common stock upon exercise of warrants, shares	240,000
Balance at Mar. 31, 2023	$ 83	$ 76,379	$ (71,614)	$ 4,848
Balance, shares at Mar. 31, 2023	8,130,628

Interim Consolidated Statemen_3

Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (2,853)	$ (3,189)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	25	21
Non-cash and accrued interest		1
Interest income and unrealized gains from marketable securities	(27)
Share-based compensation expense	412	429
Changes in assets and liabilities:
Prepaid expenses and other assets	140	177
Other payables and accrued liabilities	(900)	(446)
Net cash flows used in operating activities	(3,203)	(3,007)
Investing activities:
Purchases of property and equipment		(16)
Purchase of a marketable security	(638)
Proceeds from sale of a marketable security	1,000
Proceeds from maturities of marketable securities	2,518
Short term deposit	3
Net cash flows provided by (used in) investing activities	2,883	(16)
Decrease in cash, cash equivalents and restricted cash	(320)	(3,023)
Cash, cash equivalents and restricted cash at beginning of period	2,519	13,580
Cash, cash equivalents and restricted cash at end of period	2,199	10,557
Supplemental disclosure of cash flow information:
Cash received from interest	35
Right-of-use asset and lease liability	$ 12	$ 121

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL A. Description of business: Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock, par value $ 0.01 The Company and Microbot Israel, its sole subsidiary, are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors: To date, the Company has not generated revenues from its operations. As of March 31, 2023, the Company had cash equivalents and marketable securities balance of approximately $ 5,057 Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. While management of the Company believes that it has sufficient funds until September 2023, the Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. C. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. D. Unaudited Interim Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). Operating results for the three-month period ended March 31, 2023, are not necessarily indicative of the results that may be expected for the year ended December 31, 2023.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual audited financial statements. Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2023 and December 31, 2022: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of March 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 1,270 $ 1,270 $ - $ - Money market mutual 1,637 1,637 - - $ 2,907 $ 2,907 $ - $ - As of December 31, 2022 Total Level 1 Level 2 Level 3 Cash equivalents: U.S. treasury securities $ 1,247 $ 1,247 $ - $ - Marketable securities: U.S. treasury securities $ 3,761 $ 3,761 $ - $ - Money market mutual funds 1,999 1,999 - - $ 5,760 $ 5,760 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of March 31, 2023 and December 31, 2022. Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2023
Leases
LEASES	NOTE 3 - LEASES The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases and its sublease transactions are de minimis. Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES For the Three Months Ended March 31, 2023 2022 Cash payments and expenses $ 75 $ 93 Undiscounted maturities of operating lease payments as of March 31, 2023 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2023 (Remainder of the year) $ 224 2024 187 2025 8 Total future lease payments 419 Less imputed interest (26 ) Total lease liability balance $ 393 SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES March 31, December 31, 2023 2022 Operating leases weighted average remaining lease term (in years) 1 2 Operating leases weighted average discount rate 9 % 9 %

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 - COMMITMENTS AND CONTINGENCIES Government Grants: Microbot Israel has received grants from the Israeli Innovation Authority (“IIA”) for participation in research and development since 2013 through March 31, 2023 totaling approximately $ 1,500 In addition, as a result of the agreement with CardioSert Ltd. (“CardioSert”) on January 4, 2018, Microbot Israel took over the liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $ 530 As a result of the agreement with Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”), on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $ 925 In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to 3.0 3.5 The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of Libor per annum. The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. TRDF Agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the License Agreement”). As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between 1.5 3.0 Pursuant to the License Agreement, both parties agreed to extend the next development milestone for the Company’s Self Cleaning Shunt (SCS) project, which includes the First In Human milestone, until December 2024, and to continue to maintain the TipCat assets, which are still in a discovery phase, until December 2023. The Company in October 2022 suspended the SCS project while it evaluated alternatives for the SCS assets (mainly related patents), including seeking buyers for the assets, joint ventures or licensing arrangements, spinning off the assets into a new operating company or discontinuing the project altogether. The Company has certain obligations to seek to develop and commercialize the SCS and the TipCat assets under the License Agreement. The Company has been in discussions with TRDF with respect to the suspension of the SCS project and the status of the TipCat assets, and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, expects to return such licensed assets to TRDF in the second fiscal quarter of 2023. See “Note 6 – Subsequent Events” below. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert to acquire certain of its patent-protected technology (the “Technology”). Pursuant to the Agreement, Microbot Israel made aggregate payments of $ 300 6,738 74 The agreement may be terminated by Microbot Israel at any time for convenience upon 90-days’ notice. The agreement may be terminated by CardioSert in case the first commercial sale does not occur by the third anniversary of the date of signing of the agreement except if Microbot Israel has invested more than $ 2,000 In each of the above termination events, or in case of breach by Microbot Israel, CardioSert shall have the right to buy back the Technology from Microbot Israel for $ 1.00 Additionally, the agreement may be terminated by either party upon breach of the other (subject to cure). Microbot Israel pays CardioSert a monthly consultation fee of NIS 40 11.06 exchange rate of NIS 3.615 to the dollar See “Note 6 – Subsequent Events” below, with respect to the Company’s May 17, 2023 termination of the agreement. As of the filing date of this Quarterly Report on Form 10-Q, CardioSert has not purchased back the Technology. ATM Agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its Common Stock having an aggregate offering price of up to $ 10,000 Acquisition of Nitiloop’s Assets On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $ 8,000 ● Royalties at a rate of 3 ● Royalties at a rate of 1.5 Litigation: Litigation Resulting from 2017 Financing The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., Plaintiffs, against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020). The complaint alleges, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint seeks rescission of the SPA and return of the Plaintiffs’ $ 6,750 Mona Litigation On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to include Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934, 15 U.S.C. 78p(b), to compel Alliance and Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The case is Microbot Medical Inc. v. Alliance Investment Management, Ltd., No. 19-cv-3782-GBD (SDNY). The amount of profits was estimated in the complaint to be approximately $ 468 On October 28, 2019, Alliance filed a motion for summary judgment requesting that the Court dismiss the claims against Alliance, which was subsequently granted by the Court. On February 4, 2020, Mona answered the 16(b) claim the Company asserted against him by claiming various equitable defenses and filed a counterclaim against the Company under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming a net loss on trading the Company’s stock of approximately $ 151 On March 30, 2021, the Court issued an Order; and on March 31, 2021, the Clerk entered judgment against Mona and in favor of the Company in the amount of approximately $ 485 In June 2021, the Magistrate issued an order permitting Mona to file an Amended Counterclaim Complaint, and rejected the Company’s request to execute on the judgment. The Company filed a response to Mona’s amended counterclaim in July 2021, and in February 2023 filed a motion for summary judgment on Mona’s fraud claim on the basis of inability to demonstrate reliance or loss causation. The motion was fully briefed and submitted on May 1, 2023. On April 12, 2023, Mona filed a motion to dismiss the Company’s 16(b) claim based on a decision issued by a Magistrate Judge in an unrelated case, which held that 16(b) plaintiffs must allege an “injury in fact” resulting from a defendant’s short swing trading violation. That decision is currently on appeal, and the Company believes Mona’s motion is meritless. The Company intends to oppose the motion, which is scheduled to be fully briefed on May 24, 2023.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SHARE CAPITAL	NOTE 5 - SHARE CAPITAL Share Capital Developments: As of December 31, 2022 and March 31, 2023, the Company had, respectively, 7,890,628 8,130,628 On February 13, 2023, 240,000 0.0001 Employee Stock Option Grants: During the three months ended March 31, 2023, the Company granted to certain directors, options to purchase an aggregate of 70,000 3.48 three years

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 - SUBSEQUENT EVENTS On May 15, 2023, the Board of Directors of the Company authorized, and the Company commenced, a core-business focus program while the Company seeks to raise additional capital to continue development of the LIBERTY robotic system. This core-business focus program includes the cessation of research and development activities not related to LIBERTY, including terminating the Company’s agreement with CardioSert for that technology, and returning intellectual property relating to the SCS (Virob) and TipCat to TRDF. On May 15, 2023, in addition to the core-business focus program described above, the Board of Directors of the Company authorized, and the Company commenced, a cost reduction plan while the Company seeks to raise additional capital to continue development of the LIBERTY robotic system.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Fair value of financial instruments:	Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivables and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2023 and December 31, 2022: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of March 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 1,270 $ 1,270 $ - $ - Money market mutual 1,637 1,637 - - $ 2,907 $ 2,907 $ - $ - As of December 31, 2022 Total Level 1 Level 2 Level 3 Cash equivalents: U.S. treasury securities $ 1,247 $ 1,247 $ - $ - Marketable securities: U.S. treasury securities $ 3,761 $ 3,761 $ - $ - Money market mutual funds 1,999 1,999 - - $ 5,760 $ 5,760 $ - $ - The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of March 31, 2023 and December 31, 2022.
Contingencies	Contingencies Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required.
Recently issued accounting pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT	The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2023 and December 31, 2022: SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT As of March 31, 2023 Total Level 1 Level 2 Level 3 Marketable securities: U.S. treasury securities $ 1,270 $ 1,270 $ - $ - Money market mutual 1,637 1,637 - - $ 2,907 $ 2,907 $ - $ - As of December 31, 2022 Total Level 1 Level 2 Level 3 Cash equivalents: U.S. treasury securities $ 1,247 $ 1,247 $ - $ - Marketable securities: U.S. treasury securities $ 3,761 $ 3,761 $ - $ - Money market mutual funds 1,999 1,999 - - $ 5,760 $ 5,760 $ - $ -

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2023
Leases
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES	Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES For the Three Months Ended March 31, 2023 2022 Cash payments and expenses $ 75 $ 93
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Undiscounted maturities of operating lease payments as of March 31, 2023 are summarized as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2023 (Remainder of the year) $ 224 2024 187 2025 8 Total future lease payments 419 Less imputed interest (26 ) Total lease liability balance $ 393
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES	SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES March 31, December 31, 2023 2022 Operating leases weighted average remaining lease term (in years) 1 2 Operating leases weighted average discount rate 9 % 9 %

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Nov. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of incorporation	Aug. 02, 1988
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Cash equivalents and marketable securities	$ 5,057

SCHEDULE OF FINANCIAL ASSETS FA

SCHEDULE OF FINANCIAL ASSETS FAIR VALUE MEASUREMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable Securities [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	$ 2,907	$ 5,760
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	2,907	5,760
Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
US Treasury Securities [Member] | Marketable Securities [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	1,270	3,761
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	1,270	3,761
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
US Treasury Securities [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
US Treasury Securities [Member] | Cash Equivalents [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value		1,247
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value		1,247
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
US Treasury Securities [Member] | Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
Money Market Funds [Member] | Marketable Securities [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	1,637	1,999
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value	1,637	1,999
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value
Money Market Funds [Member] | Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and Cash Equivalents [Line Items]
Assets, fair value

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Cash payments and expenses	$ 75	$ 93

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Leases
2023 (Remainder of the year)	$ 224
2024	187
2025	8
Total future lease payments	419
Less imputed interest	(26)
Total lease liability balance	$ 393

SCHEDULE OF SUPPLEMENTAL INFORM

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases
Operating leases weighted average remaining lease term (in years)	1 year	2 years
Operating leases weighted average discount rate	9%	9%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ / shares in Units, ₪ in Thousands, $ in Thousands							1 Months Ended	3 Months Ended
	Oct. 06, 2022 USD ($)	Mar. 31, 2021 USD ($)	Feb. 04, 2020 USD ($)	Apr. 28, 2019 USD ($)	Jan. 04, 2018 USD ($) $ / shares shares	Jan. 04, 2018 ILS (₪) shares	Jun. 30, 2012	Mar. 31, 2023 USD ($)	Jun. 10, 2021 USD ($)
Loss Contingencies [Line Items]
Stock issued during period, value, new issues
Net loss on trading of common stock			$ 151
Joseph Mona [Member]
Loss Contingencies [Line Items]
Purchase price of plaintiffs		$ 485
Device [Member]
Loss Contingencies [Line Items]
Royalties percentage	3%
Integrated Product [Member]
Loss Contingencies [Line Items]
Royalties percentage	1.50%
Securities Purchase Agreement [Member]
Loss Contingencies [Line Items]
Purchase price of plaintiffs								$ 6,750
Israeli Innovation Authority [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales								3%
Israeli Innovation Authority [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales								3.50%
Israeli Innovation Authority [Member] | CardioSert Ltd [Member]
Loss Contingencies [Line Items]
Repayment of government grants					$ 530
Israeli Innovation Authority [Member] | Nitiloop [Member]
Loss Contingencies [Line Items]
Repayment of government grants	$ 925
Technion Research and Development Foundation Limited [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales							1.50%
Technion Research and Development Foundation Limited [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales							3%
CardioSert Ltd [Member] | Technology [Member]
Loss Contingencies [Line Items]
Payment to acquire intangible assets					$ 300
Number of common shares issued for acquisition | shares					6,738	6,738
Number of common shares issued for acquisition, value					$ 74
Buy back amount per patent | $ / shares					$ 1
Consulting fee description					Additionally, the agreement may be terminated by either party upon breach of the other (subject to cure). Microbot Israel pays CardioSert a monthly consultation fee of NIS40 (or approximately US$11.06, based on an exchange rate of NIS 3.615 to the dollar) covering up to 60 consulting hours per month, relating to the development of the Technology.	Additionally, the agreement may be terminated by either party upon breach of the other (subject to cure). Microbot Israel pays CardioSert a monthly consultation fee of NIS40 (or approximately US$11.06, based on an exchange rate of NIS 3.615 to the dollar) covering up to 60 consulting hours per month, relating to the development of the Technology.
Monthly consultation fee | ₪						₪ 40
Monthly consultation fee in USD | $ / shares					$ 11.06
Currency exchange rate, description					exchange rate of NIS 3.615 to the dollar	exchange rate of NIS 3.615 to the dollar
CardioSert Ltd [Member] | Minimum [Member] | Technology [Member]
Loss Contingencies [Line Items]
Investments					$ 2,000
H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]
Loss Contingencies [Line Items]
Offering costs									$ 10,000
Stock issued during period, value, new issues	$ 8,000
Alliance Investment Management, Ltd. [Member]
Loss Contingencies [Line Items]
Litigation settlement				$ 468
2013 through March 31, 2023 [Member] | Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Total grants obtained								$ 1,500

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2023	Feb. 13, 2023	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock, shares issued	8,130,628		7,890,628
Common stock, shares outstanding	8,130,628		7,890,628
Class of warrant or right, outstanding		240,000
Exercise price		$ 0.0001
Director [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of stock options granted	70,000
Weighted-average exercise price per share, granted	$ 3.48
Stock options vesting period	3 years